IP Library Granted Patent US 10,857,152
Granted Patent B2
US 10,857,152 · App. 15/959,482 · Granted Dec 8, 2020

Methods and compositions for treating viral or virally-induced conditions

Inventors: Ronald J. Berenson (Mercer Island, WA); Douglas V. Faller (Weston, MA)
Assignees: TRUSTEES OF BOSTON UNIVERSITY; VIRACTA THERAPEUTICS, INC.
A61K31/506A61K9/0053A61K31/165A61K31/167A61K31/18A61K31/19A61K31/27A61K31/4045A61K31/4402A61K31/473A61K31/513A61K31/52A61K31/522A61K38/12A61K38/15A61K45/06Y02A50/467
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,857,152
App. No.
15/959,482
Granted
Dec 8, 2020
Kind
B2
Abstract

Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.

Claims (11)

1. A method for treating and/or preventing a viral or virally-induced condition comprising administering CHR-3996, wherein the CHR-3996 is administered at less than 2 mg/kg per dose, and an antiviral agent, wherein the antiviral agent is selected from the group consisting of valganciclovir, ganciclovir, acyclovir, famciclovir, and combinations thereof, wherein the viral or virally-induced condition is caused by a DNA virus.

2. The method of claim 1 , wherein the DNA virus is a herpes virus.

3. The method of claim 1 , wherein the DNA virus is an Epstein-Barr virus.

4. The method of claim 1 , wherein the DNA virus is a cytomegalovirus.

5. The method of claim 1 , wherein the DNA virus is a varicella zoster virus.

6. The method of claim 1 , wherein the viral or virally-induced condition is a cancer selected from the group of lymphoma, chronic lymphocytic leukemia, nasopharyngeal carcinoma, gastric cancer, or Kaposi's sarcoma.

7. The method of claim 1 , wherein the antiviral agent is valganciclovir.

8. The method of claim 1 , wherein the antiviral agent is ganciclovir.

9. The method of claim 1 , wherein the antiviral agent is acyclovir.

10. The method of claim 1 , wherein the antiviral agent is famciclovir.

11. The method of claim 1 , wherein the CHR-3996 and the antiviral agent are administered once daily.

Assignments (6)
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 23, 2025
From: VIRACTA SUBSIDIARY, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 070000/0001 →
CHANGE OF NAME Recorded Jun 18, 2024
From: VIRACTA THERAPEUTICS, INC.
To: VIRACTA SUBSIDIARY, INC.
Reel/Frame 067761/0143 →
CHANGE OF NAME Recorded Jul 28, 2020
From: HEMAQUEST PHARMACEUTICALS, INC.
To: VIRACTA THERAPEUTICS, INC.
Reel/Frame 053336/0020 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED AT REEL: 053208 FRAME: 0883. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 28, 2020
From: BERENSON, RONALD J.
To: HEMAQUEST PHARMACEUTICALS, INC.
Reel/Frame 053336/0023 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2020
From: FALLER, DOUGLAS V.
To: TRUSTEES OF BOSTON UNIVERSITY
Reel/Frame 053198/0854 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2020
From: BERENSON, RONALD J.
To: HERMAQUEST PHARMACEUTICALS, INC.
Reel/Frame 053208/0883 →
Continuity (7)
Continuation 15335776 · Oct 27, 2016
Continuation 14728592 · Jun 2, 2015
Continuation 13912637 · Jun 7, 2013
Continuation 13046555 · Mar 11, 2011
Provisional Application 61430931 · Jan 7, 2011
Provisional Application 61313052 · Mar 11, 2010
Related Publication 20190091221A1 · Mar 28, 2019